LI
AUPH icon

Leap Investments’s Aurinia Pharmaceuticals AUPH Stock Holding History

Leap Investments’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15,500
Closed -$225K – 400
2020
Q1 		$225K Buy
+15,500
New +$273K 0.33% 129

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Leap Investments's AUPH Position: Q2 2020 in Review

Leap Investments sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2020, closing a stake of 15,500 shares — an estimated $225K sold.

Leap Investments first reported a position in AUPH in Q1 2020 and held it in 1 quarter. The position peaked at $225K in Q1 2020. 132 funds tracked by Wall St. Rank hold AUPH as of Q2 2020.

  • Leap Investments reported no remaining Aurinia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Leap Investments sold 15,500 Aurinia Pharmaceuticals shares in Q2 2020, an estimated $225K.
  • Leap Investments first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Leap Investments's Aurinia Pharmaceuticals position peaked at $225K in Q1 2020.
  • 132 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.